138 related articles for article (PubMed ID: 37400016)
1. The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis.
Li Z; Hu Y; Zou B
J Hepatol; 2023 Oct; 79(4):e157-e162. PubMed ID: 37400016
[No Abstract] [Full Text] [Related]
2. Immunogenicity of COVID-19 vaccines in patients with cirrhosis: Expected advantage for additional dose of vaccine.
Daungsupawong H; Wiwanitkit V
Hum Vaccin Immunother; 2024 Dec; 20(1):2334920. PubMed ID: 38593300
[No Abstract] [Full Text] [Related]
3. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.
Wang J; Zhang Q; Ai J; Liu D; Liu C; Xiang H; Gu Y; Guo Y; Lv J; Huang Y; Liu Y; Xu D; Chen S; Li J; Li Q; Liang J; Bian L; Zhang Z; Guo X; Feng Y; Liu L; Zhang X; Zhang Y; Xie F; Jiang S; Qin W; Wang X; Rao W; Zhang Q; Tian Q; Zhu Y; Cong Q; Xu J; Hou Z; Zhang N; Zhang A; Zu H; Wang Y; Yan Z; Du X; Hou A; Yan Y; Qiu Y; Wu H; Hu S; Deng Y; Ji J; Yang J; Huang J; Zhao Z; Zou S; Ji H; Ge G; Zhong L; He S; Yan X; Yangzhen BB; Qu C; Zhang L; Yang S; Gao X; Lv M; Zhu Q; Xu X; Zeng QL; Qi X; Zhang W
Hepatol Int; 2022 Jun; 16(3):691-701. PubMed ID: 35403977
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.
Cao Z; Zhang C; Zhao S; Sheng Z; Xiang X; Li R; Qian Z; Wang Y; Chen B; Li Z; Liu Y; An B; Zhou H; Cai W; Wang H; Gui H; Xin H; Xie Q
Infect Dis Poverty; 2022 May; 11(1):56. PubMed ID: 35578350
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.
Ouyang L; Lei G; Gong Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2326316. PubMed ID: 38466197
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.
König M; Torgauten HM; Tran TT; Holmøy T; Vaage JT; Lund-Johansen F; Nygaard GO
JAMA Neurol; 2022 Mar; 79(3):307-309. PubMed ID: 35072702
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.
Ai J; Wang J; Liu D; Xiang H; Guo Y; Lv J; Zhang Q; Li J; Zhang X; Li Q; Liang J; Guo X; Feng Y; Liu L; Zhang X; Qin W; Wang X; Rao W; Zhang Q; Tian Q; Zhang Y; Xie F; Jiang S; Yan Y; Qiu Y; Wu H; Hou Z; Zhang N; Zhang A; Ji J; Yang J; Huang J; Zhao Z; Gu Y; Bian L; Zhang Z; Zou S; Ji H; Ge G; Du X; Hou A; Zhu Y; Cong Q; Xu J; Zu H; Wang Y; Yan Z; Yan X; BianBa Y; Ci Q; Zhang L; Yang S; Gao X; Zhong L; He S; Liu C; Huang Y; Liu Y; Xu D; Zhu Q; Xu X; Lv M; Zhang W; Qi X
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1516-1524.e2. PubMed ID: 34942370
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of different platforms of COVID-19 vaccines given as a third (booster) dose in healthy adults.
Lin Z; Cheng M; Zhu F; Yang X; Zuo J; He S
J Med Virol; 2022 Sep; 94(9):4047-4052. PubMed ID: 35521674
[No Abstract] [Full Text] [Related]
10. COVID-19 vaccination and liver disease.
Ozaka S; Kobayashi T; Mizukami K; Murakami K
World J Gastroenterol; 2022 Dec; 28(48):6791-6810. PubMed ID: 36632314
[TBL] [Abstract][Full Text] [Related]
11. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
Iavarone M; Tosetti G; Facchetti F; Topa M; Er JM; Hang SK; Licari D; Lombardi A; D'Ambrosio R; Degasperi E; Loglio A; Oggioni C; Perbellini R; Caccia R; Bandera A; Gori A; Ceriotti F; Scudeller L; Bertoletti A; Lampertico P
Dig Liver Dis; 2023 Feb; 55(2):160-168. PubMed ID: 36266209
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
14. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
15. Immediate reactions after mRNA SARS-CoV-2 vaccination.
Jeimy S; Wong T; Song C
CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
[No Abstract] [Full Text] [Related]
16. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
17. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.
Mehta G; Riva A; Ballester MP; Uson E; Pujadas M; Carvalho-Gomes Â; Sahuco I; Bono A; D'Amico F; Viganò R; Diago E; Lanseros BT; Inglese E; Vazquez DM; Sharma R; Tsou HLP; Harris N; Broekhoven A; Kikkert M; Morales SPT; Myeni SK; Riveiro-Barciela M; Palom A; Zeni N; Brocca A; Cussigh A; Cmet S; Escudero-García D; Stocco M; Natola LA; Ieluzzi D; Paon V; Sangiovanni A; Farina E; di Benedetto C; Sánchez-Torrijos Y; Lucena-Varela A; Román E; Sánchez E; Sánchez-Aldehuelo R; López-Cardona J; Canas-Perez I; Eastgate C; Jeyanesan D; Morocho AE; Di Cola S; Lapenna L; Zaccherini G; Bongiovanni D; Zanaga P; Sayaf K; Hossain S; Crespo J; Robles-Díaz M; Madejón A; Degroote H; Fernández J; Korenjak M; Verhelst X; García-Samaniego J; Andrade RJ; Iruzubieta P; Wright G; Caraceni P; Merli M; Patel VC; Gander A; Albillos A; Soriano G; Donato MF; Sacerdoti D; Toniutto P; Buti M; Duvoux C; Grossi PA; Berg T; Polak WG; Puoti M; Bosch-Comas A; Belli L; Burra P; Russo FP; Coenraad M; Calleja JL; Perricone G; Berenguer M; Claria J; Moreau R; Arroyo V; Angeli P; Sánchez C; Ampuero J; Piano S; Chokshi S; Jalan R;
Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37870985
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
19. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
